TACE inhibition: A new approach to treating inflammation

Expert Opinion on Investigational Drugs

Volumn 11, Issue 7, 2002, Pages 1003-1006

  Doggrell, Sheila A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Arthritis; GW3333; TNF converting enzyme inhibition

Indexed keywords

3 (FORMYLHYDROXYAMINO) 2 METHYL 1 PROPYL 4 METHYLPENTANOIC ACID[2 METHYL 1 (2 PYRIDYLCARBAMOYL) 1 BUTYL]AMIDE; CYTOKINE; ENZYME INHIBITOR; ETANERCEPT; GLUCOCORTICOID; GW 3333; INFLIXIMAB; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; ADAM PROTEIN; AMINOPYRIDINE DERIVATIVE; DIPEPTIDE; IMMUNOGLOBULIN G; METALLOPROTEINASE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; RHEUMATOID ARTHRITIS; SIDE EFFECT; ANIMAL; ARTHRITIS; BIOSYNTHESIS; BLOOD; CHEMISTRY; DRUG ANTAGONISM; DRUG COMBINATION; RAT;

AMINOPYRIDINES; ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DIPEPTIDES; DRUG THERAPY, COMBINATION; HUMAN; IMMUNOGLOBULIN G; METALLOENDOPEPTIDASES; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; ADAM PROTEINS; ANIMALS; HUMANS;

EID: 0035986907     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.7.1003     Document Type: Article

References (23)

1. Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases
2. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial
3. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
4. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
5. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised Phase III trial
6. Infliximab and methotrexate in the treatment of rheumatoid arthritis
7. The role of tumor necrosis factor in health and disease
8. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by matrix metalloproteinase inhibitors
9. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF-α processing
10. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo
11. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
12. Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-α
13. Regulation of tumour necrosis factor-α by a metalloproteinase inhibitor
14. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
15. A metalloproteinase inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes
16. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor
17. Diptheria toxin endocytosis and membrane translocation are dependent on the intact membrane-anchored receptor (HB-EGF): Studies on the cell-associated receptor cleaved by a metalloprotease in phorbol-ester-treated cells
18. Drug-induced systemic lupus erythematosus associated with etanercept therapy
19. Potential role of TNF-α in the pathogenesis of insulin resistance and Type 2 diabetes
20. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis
21. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
22. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo
23. Noble 2-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-isoindolinone derivatives. Part I: Synthesis and SAR studies for the inhibition of TNF-alpha production